Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic)

被引：0
|
作者：
Mohamed Hamidou
Antoine Néel
Joel Poupon
Zahir Amoura
Mikael Ebbo
Jean Sibilia
Jean-Francois Viallard
Benjamin Gaborit
Christelle Volteau
Jean Benoit Hardouin
Eric Hachulla
François Rieger
机构：
[1] Department of Internal Medicine,Department of Biological Toxicology
[2] CHU Nantes,Department of Internal Medicine 2, Centre National de Référence pour le Lupus, Institut E3M
[3] Nantes Université,Service de Médecine Interne
[4] AP-HP,Department of Rheumatology
[5] Lariboisière Hospital,Department of Internal Medicine
[6] University Paris VII,Plateforme de Méthodologie et Biostatistiques, CHU Nantes
[7] Hôpital Pitié-Salpétrière,Department of Internal Medicine, Centre de Référence des Maladies Autoimmunes Systémiques Rares du Nord et Nord
[8] Aix Marseille Univ,Ouest de France (CeRAINO)
[9] APHM,undefined
[10] CNRS,undefined
[11] INSERM,undefined
[12] CIML,undefined
[13] Hôpital de la Timone,undefined
[14] University of Strasbourg,undefined
[15] Haut-Lévêque University Hospital,undefined
[16] Université de Nantes,undefined
[17] INSERM UMR 1246-SPHERE,undefined
[18] Université de Nantes,undefined
[19] University of Lille,undefined
[20] MEDSENIC,undefined
[21] SAS,undefined
[22] a company with CNRS participation,undefined
来源：
Arthritis Research & Therapy | / 23卷
关键词：
Systemic lupus erythematosus; Autoimmune diseases; Treatment; Arsenic trioxide; Phase II clinical trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of Anifrolumab in Adults with Systemic Lupus Erythematosus
    Chatham, W. Winn
    Furie, Richard
    Saxena, Amit
    Brohawn, Philip
    Schwetje, Erik
    Abreu, Gabriel
    Tummala, Raj
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [22] The efficacy of low-dose mycophenolate mofetil for treatment of lupus nephritis in Taiwanese patients with systemic lupus erythematosus
    Weng, Meng-Yu
    Weng, Chia-Tse
    Liu, Ming-Fei
    CLINICAL RHEUMATOLOGY, 2010, 29 (07) : 771 - 775
  • [23] The efficacy of low-dose mycophenolate mofetil for treatment of lupus nephritis in Taiwanese patients with systemic lupus erythematosus
    Meng-Yu Weng
    Chia-Tse Weng
    Ming-Fei Liu
    Clinical Rheumatology, 2010, 29 : 771 - 775
  • [24] Two Cases of Refractory Thrombocytopenia in Systemic Lupus Erythematosus that Responded to Intravenous Low-Dose Cyclophosphamide
    Park, Hee-Jin
    Kang, Mi-il
    Kang, Yoon
    Chung, Soo-jin
    Lee, Sang-Won
    Park, Yong-Beom
    Lee, Soo-Kon
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2013, 28 (03) : 472 - 475
  • [25] Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial
    Chakravarty, Eliza F.
    Utset, Tammy
    Kamen, Diane L.
    Contreras, Gabriel
    McCune, W. Joseph
    Aranow, Cynthia
    Kalunian, Kenneth
    Massarotti, Elena
    Clowse, Megan E. B.
    Rovin, Brad H.
    Lim, S. Sam
    Majithia, Vikas
    Dall'Era, Maria
    Looney, R. John
    Erkan, Doruk
    Saxena, Amit
    Olsen, Nancy J.
    Ko, Kichul
    Guthridge, Joel M.
    Goldmuntz, Ellen
    Springer, Jessica
    D'Aveta, Carla
    Keyes-Elstein, Lynette
    Barry, Bill
    Pinckney, Ashley
    Mcnamara, James
    James, Judith A.
    LANCET RHEUMATOLOGY, 2024, 6 (03): : e168 - e177
  • [26] Safety and Efficacy of Subcutaneous Tocilizumab in Systemic Sclerosis: Results from the Open-Label Period of a Phase 3 Trial
    Khanna, Dinesh
    Lin, Celia J. F.
    Spotswood, Helen
    Siegel, Jeffrey
    Furst, Daniel
    Denton, Christopher
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [27] Safety and Efficacy of Allogeneic Umbilical Cord-Derived Mesenchymal Stem Cells in Patients with Systemic Lupus Erythematosus: Results of an Open-Label Phase I Study
    Kamen, Diane L.
    Nietert, Paul J.
    Wang, Hongjun
    Duke, Tara
    Cloud, Colleen
    Robinson, Angela
    Gilkeson, Gary S.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [28] Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years
    Zhang, Fengchun
    Zheng, Jie
    Li, Yang
    Wang, Guochun
    Wang, Mingjun
    Su, Yin
    Gu, Jieruo
    Li, Xingfu
    Bass, Damon
    Chu, Myron
    Curtis, Paula
    DeRose, Kathleen
    Kurrasch, Regina
    Lowe, Jenny
    Meizlik, Paige
    Roth, David A.
    RMD OPEN, 2022, 8 (01):
  • [29] Initial Findings of an Open-Label Trial of Low-Dose Naltrexone for Symptomatic Mesenteric Panniculitis
    Roginsky, Grigory
    Alexoff, Aimee
    Ehrenpreis, Eli D.
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2015, 49 (09) : 794 - 795
  • [30] SAFETY AND EFFICACY OF INTRAVENOUS BELIMUMAB IN PATIENTS WITH LUPUS NEPHRITIS: A 6-MONTH OPEN-LABEL EXTENSION
    Rovin, Brad
    Furie, Richard
    Houssiau, Frederic A.
    Contreras, Gabriel
    Teng, Y. K. O.
    Curtis, Paula
    Madan, Anuradha
    Jones-Leone, Angela
    Gonzalez-Rivera, Tania
    Okily, Mohamed
    Roth, David
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36
12345